Participants will be randomised to either:
- Experimental intervention: Standard Care + Candesartan + Repagermanium
- Control #1: Standard Care + Candesartan + Placebo (Repagermanium)
- Control #2: Standard Care + Placebo (Candesartan) + Placebo (Repagermanium)
Ann: DMX-200 CLARITY COVID-19 Study Approval in India, page-5
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.5¢ |
Change
0.045(11.0%) |
Mkt cap ! $253.4M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 46.5¢ | 41.0¢ | $3.375M | 7.571M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 149191 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 195819 | 4 |
View Market Depth
| Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |